Procore signs multi-year strategic collaboration agreement with AWS
NEWPORT BEACH, Calif. - Evolus, Inc. (NASDAQ:EOLS) saw its shares climb 2.5% after the performance beauty company reported fourth-quarter revenue that exceeded analyst expectations and provided an upbeat outlook for 2025.
The aesthetic product maker posted Q4 revenue of $79 million, surpassing the consensus estimate of $76.96 million and marking a 30% increase from the same period last year. However, the company reported a loss of -$0.11 per share, falling short of analysts’ projections for earnings of $0.02 per share.
For the full year 2024, Evolus achieved record net revenue of $266.3 million, representing 32% YoY growth and reaching the high end of its previously provided guidance range.
Looking ahead, the company forecasts 2025 revenue between $345 million and $355 million, indicating 30% to 33% growth from 2024 results. This outlook aligns with the current analyst consensus of $352 million.
"We reached a significant inflection point in 2024, achieving full-year profitability ahead of expectations while delivering our fifth consecutive year of revenue growth exceeding 30%," said David Moatazedi, President and CEO of Evolus.
Evolus plans to launch its newly FDA-approved Evolysse hyaluronic acid filler in the second quarter of 2025. The company expects Evolysse and Estyme injectable gels to contribute 8-10% of total revenue for the full year 2025.
The company also reiterated its goal of reaching at least $700 million in net revenue by 2028, representing a 27% compound annual growth rate from 2024 levels.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.